Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of BGY-1601-VT in Women With Acute Vaginal Infection
NCT06450990Phase 2Not yet recruiting
- Sponsor
- Nexbiome Therapeutics
- Start
- Jul 2024
- Primary completion
- Dec 2025
- Modality
- Live Biotherapeutic Products
01
Overview
Phase 2, randomised, double-blind trial of BGY-1601-VT in bacterial vaginosis (BV) and vulvovaginal candidiasis (VVC) (3 arms), sponsored by Nexbiome Therapeutics. Primary endpoint: Efficacy of BGY-1601-VT to treat acute vaginal infection at 7 days. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
BGY-1601-VT
03
Conditions
bacterial vaginosis (BV)vulvovaginal candidiasis (VVC)
Beyond the preview
Go deeper on NCT06450990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06450990.